BioWorld by Clarivate Releases Comprehensive 2024 Year in Review
Rhea-AI Summary
BioWorld, published by Clarivate (NYSE:CLVT), has released its comprehensive 2024 Year in Review series analyzing key developments in biopharma, medtech, and scientific innovation. The report highlights significant therapeutic breakthroughs in psychiatry, oncology, women's health, and infectious diseases.
Key findings include the industry's resilience despite challenges, with biopharma financing and deal values rebounding amid over 18,000 job losses. Notable developments include GLP-1 receptor agonists' expansion into new therapeutic areas, significant progress in AI-driven medtech in APAC, and breakthrough cancer research data from trials like Checkmate-067 and Keynote-006.
The report also covers important regulatory changes, including the end of the Chevron doctrine affecting agency authority, and Medicare coverage challenges for emerging technologies. European biotech funding showed improvement in 2024, particularly in antibody-drug conjugates (ADCs) and CNS treatments.
Positive
- Biopharma financing and deal values showed significant rebound in 2024
- European biotech funding exceeded 2020 levels
- Strong M&A activity reported
- Expansion of GLP-1 receptor agonists into new therapeutic areas
Negative
- Over 18,000 job losses in the sector during 2024
- Tempered IPO market conditions
- Reduced total M&A value despite steady pace
- Medicare coverage limitations for emerging technologies
News Market Reaction – CLVT
On the day this news was published, CLVT gained 0.20%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Series Recaps Biopharma, MedTech, and Science Trends and Breakthroughs That Shaped the Year
As the biopharma and med-tech industries continue to evolve, 2024 proved to be a landmark year. The comprehensive recap by BioWorld highlights therapeutic breakthroughs in psychiatry, oncology, women's health and infectious diseases, alongside economic highs and lows that challenged the global landscape. The series also examines regulatory changes, including
Lynn Yoffee, Publisher of BioWorld, said: "The 2024 Year in Review series provides a powerful lens into the transformative events and advancements that shaped our industry this year. With our team of expert journalists and analysts, we strive to distill complex developments into actionable insights, empowering stakeholders to make informed decisions as they navigate 2025 and beyond."
Key Highlights of the BioWorld 2024 Year in Review Series:
BioWorld Year in Review: This section highlights the top mergers and acquisitions, licensing deals, financings, and first approvals of 2024. It also provides insights into key therapeutic trends such as GLP-1 receptor agonists, antibody-drug conjugates (ADCs), psychedelics, and the evolving role of precision psychiatry, alongside innovations spurred by the pandemic. Featured articles include:
- The Economy: Top Biopharma Trends of 2024 by Amanda Lanier
A comprehensive infographic that highlights how 2024 showcased resilience amidst challenges, with biopharma financing and deal values rebounding significantly despite over 18,000 job losses and a tempered IPO market. Spotlights include record-high deal values, a steady M&A pace with reduced total value, and a slightly increased rate of workforce reductions compared to 2023. - Year's top US court cases to present new challenges for 2025 by Mari Serebrov
The Loper Bright decision ended the Chevron doctrine, curbing agency authority and reshaping regulatory dynamics for 2025. Meanwhile, Gilead's$40 million - European VC improves in 2024, driven by ADCs and CNS, inflammatory drugs by Nuala Moran
European biotech funding improved in 2024, with venture capital raised exceeding 2020 levels but still trailing the pandemic peak. Investors favored later-stage programs with clearer paths to exits, while antibody-drug conjugates (ADCs) and central nervous system (CNS) assets drew significant interest. Despite challenges like closed public markets and antimicrobial fragility, optimism for 2025 is growing, fueled by expected macroeconomic improvements and strong M&A activity. - GLP-1 receptor agonists continue their global victory tour by Anette Breindl
GLP-1 receptor agonists (GLP-1RAs) had a transformative 2024, expanding into new therapeutic indications, including FDA approval for treating obstructive sleep apnea in adults with obesity, while continuing to demonstrate benefits in cardiovascular health, kidney disease, and other conditions. Despite their success, GLP-1RAs remain treatments rather than cures for underlying conditions like diabetes, prompting ongoing research into root-cause solutions.
BioWorld MedTech Year in Review: This section recaps key med-tech and diagnostic breakthroughs, covering cutting-edge advancements in brain mapping and pregnancy health, as well as regulatory developments expected to impact the sector in 2025. Coverage includes:
- AI drives financings, approvals for APAC med-tech in 2024 By Marian (YoonJee) Chu
In 2024, AI spurred significant financings and approvals in APAC med-tech, leveraging regional strengths like talent pools, data infrastructure, and government support. Key highlights included AI-powered IPOs, billion-dollar pharma collaborations, and national investments, solidifying APAC's role in AI-driven healthcare innovation. - Medicare coverage issues abound in 2024 by Mark McCarty
In 2024, Medicare faced challenges in covering emerging technologies, with the new TCET policy offering limited scope. Coverage for digital health and SaaS remained stalled due to outdated benefit categories. Meanwhile, Medicare's reimbursement rates for radiation oncology and skin substitutes sparked controversy.
BioWorld Science Year in Review: This section explores key research milestones, featuring global collaborations in infectious diseases, breakthroughs in curable tumors and innovations in women's health and neuroscience. Key highlights include:
- The map for a journey to the center of the brain by Mar de Miguel
The year 2024 marks a milestone with the end of a long journey: a complete cellular map of the fruit fly brain, Drosophila melanogaster, and a cubic millimeter of the human brain. The adventure is just beginning for the thinking species Homo sapiens. - Progress in cancer research, even the toughest types by Mar de Miguel and Anette Breindl
Among the most profound results presented at the 2024 European Society for Medical Oncology Congress were the 10-year data from the Checkmate-067 and Keynote-006 trials, the phase III trials that tested Opdivo (nivolumab, Bristol Myers Squibb Co.) and Keytruda (pembrolizumab, Merck & Co. Inc.) as first-line agents in advanced or metastatic melanoma.
The series also includes the BioWorld editorial picks for the "Best of 2024," dynamic infographics summarizing key data, and a global perspective on funding and policy changes across
To access the full BioWorld special series, visit https://www.bioworld.com/special_reports.
Join the conversation and mention BioWorld on X and LinkedIn as well as Clarivate for Life Sciences & Healthcare on X and LinkedIn.
About BioWorld
With writers and editors stationed around the globe, BioWorld published by Clarivate, reports the breaking news - and provides key perspective on thousands of therapeutics and devices in development, the companies behind those candidates, the business development transactions that evolve the markets, and the regulatory hurdles that both challenge and guard the processes. BioWorld has a long tradition of excellence in journalism. Collectively, the news services have been honored with 70 awards dating back to 1998.
About Clarivate
Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.Clarivate.com.
Media Contact:
Catherine Daniel
Director, External Communications, Life Sciences & Healthcare
newsroom@Clarivate.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/bioworld-by-clarivate-releases-comprehensive-2024-year-in-review-302352663.html
SOURCE Clarivate Plc
FAQ
What were the key therapeutic trends highlighted in Clarivate's (CLVT) 2024 BioWorld review?
How did European venture capital perform for Clarivate (CLVT) BioWorld in 2024?
What were the major regulatory changes reported in Clarivate's (CLVT) 2024 BioWorld review?
How did the biopharma job market perform according to Clarivate's (CLVT) 2024 report?
